Stoke director granted 30,782 stock options
Stoke Therapeutics director Clare Kahn received a new stock option award covering 30,782 shares of Common Stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Stoke Therapeutics director Clare Kahn received a new stock option award covering 30,782 shares of Common Stock. The option has an exercise price of $32.79 per share and expires in 2036. It vests in 12 equal quarterly installments starting July 1, 2026, contingent on continued service.
Insider Trade Summary
Grant/Award: 30,782 shares
Grant/Award
1 txn
Insider
Kahn Clare
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 30,782 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 30,782 contracts (Direct)
Footnotes (1)
- F1. The option award shall vest as to 1/12 of the total award quarterly on the first calendar day of each July, October, January, and April, with the first tranche vesting on July 1, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.
Key Figures
Option shares granted: 30,782 shares
Exercise price: $32.79 per share
Shares after transaction: 30,782 options
+3 more
6 metrics
Option shares granted
30,782 shares
Stock Option (Right to Buy) underlying Common Stock
Exercise price
$32.79 per share
Conversion or exercise price of the option
Shares after transaction
30,782 options
Total derivative securities following the grant
Expiration date
April 2, 2036
Option expiration date
Vesting start date
July 1, 2026
First tranche of quarterly vesting
Vesting pattern
1/12 quarterly
Vests quarterly on first day of July, October, January, April
Key Terms
Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
exercise price financial
"conversion_or_exercise_price: "32.7900""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The option award shall vest as to 1/12 of the total award quarterly"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: "2036-04-02T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Clare Kahn report at Stoke Therapeutics (STOK)?
Clare Kahn reported receiving a stock option grant for 30,782 shares of Stoke Therapeutics Common Stock. The award is a compensation-related option, not an open-market share purchase or sale, and gives her the right to buy shares at a fixed exercise price in the future.
What are the key terms of Clare Kahn’s new stock option in STOK?
The option covers 30,782 underlying shares with a $32.79 exercise price and expires in 2036. It was granted at no cost per option share and represents a right to buy stock rather than an immediate stock purchase in the market.
How does the vesting schedule work for Clare Kahn’s Stoke Therapeutics option grant?
The option vests as to one-twelfth of the total grant quarterly on the first calendar day of July, October, January, and April. The first tranche vests July 1, 2026, and vesting requires Kahn’s continued service with Stoke Therapeutics through each vesting date.
How many Stoke Therapeutics options does Clare Kahn hold after this transaction?
Following this grant, Kahn is reported as holding 30,782 stock options related to Stoke Therapeutics Common Stock. This figure reflects the awarded option position from this filing, with vesting over time and an expiration date in 2036, assuming service-based conditions are satisfied.
AI-generated analysis. How Rhea-AI works. Not financial advice.
